Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PIN1 | Q13526 | 8/20 | 0.49 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1917009 | 0.81 | STK17A (0.72) | MAPTPOLBSMN1; SMN2PKMSTK17A | |
| SCHEMBL2061728 | 0.81 | POLB (0.54) | MAPTPOLBSMN1; SMN2PKMSTK17A | |
| SCHEMBL12876599 | 0.80 | L3MBTL1 (0.71) | MAPTPOLBPKML3MBTL1PIN1 | |
| SCHEMBL3158536 | 0.80 | PIN1 (0.55) | MAPTPOLBSMN1; SMN2PKML3MBTL1 | |
| SCHEMBL1918606 | 0.80 | PIN1 (0.49) | MAPTL3MBTL1PIN1STK17APRKCQ | |
| SCHEMBL1804900 | 0.79 | PIN1 (0.57) | MAPTL3MBTL1PIN1STK17APRKCQ | |
| SCHEMBL4191611 | 0.79 | L3MBTL1 (0.66) | MAPTL3MBTL1PIN1STK17AGAA | |
| SCHEMBL14941801 | 0.79 | PIN1 (0.51) | MAPTL3MBTL1PIN1STK17APRKCQ | |
| SCHEMBL3182626 | 0.79 | PRKCQ (0.50) | MAPTPOLBSMN1; SMN2PKMSTK17A | |
| SCHEMBL5155732 | 0.77 | L3MBTL1 (0.53) | MAPTSMN1; SMN2L3MBTL1PIN1STK17A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113463-A1 | PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-7662819-B2 | Pteridinone derivatives for use as stearoyl CoA desaturase inhibitors | GILEAD PALO ALTO, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| EP-2131844-A1 | PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | CV Therapeutics Inc. (US) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008123891-A1 | PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | CV THERAPEUTICS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20080249100-A1 | PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | LIGAND PHARMACEUTICALS INCORPORATED | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113463-A1 | PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, COASY | MAPT 3976/4885POLB 2581/4885SMN1; SMN2 3378/4885 |
| US-20080249100-A1 | PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, COASY | MAPT 3976/4885POLB 2581/4885SMN1; SMN2 3378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.